The number of people in the United States with sickle cell disease or anemia as a result of a sickle cell erythropoietic dysfunction is 1.0 million annually. Among persons with sickle cell disease or anemia, many are asymptomatic.
There are multiple options for both treatment and prevention of anemia, sickle cell. For patients with sickle cell, a regular intake of folic acid along with calcium and vitamin B12 supplements can aid in the prevention and management of sickle cell anemia.
Results from a recent paper emphasizes on the importance of maintaining patient's self-management and good compliance to the prescription medications to reduce morbid consequences of anemia, such as poor physical performance and decreased cognitive process, which can be cured only with proper treatment.
In the absence of blood film, sickle cell anemia is readily identifiable. Other symptoms of anemia, which are also present in SCD, will be outlined.
Sickle cell anemia (SCA) is a genetic disease that causes people to have a sickle cell. People of African descent (Afrac) are most affected by SCA. Sickle cell trait (beta thalassemia-hemoglobin C and Hb, S) is also a condition that affects more than two percent of all African Americans. About 5% of African Americans have sickle cell trait.\n
Sickle cell disease is a disorder in the production of red blood cells (erythrocytes). The result of this disease is anemia. Red blood cells are produced by immature erythroid precursors, which make all cells of the skeleton and bone marrow. Sudden destruction of erythroid precursors occurs and a shortage is present in the production of red blood cells. Anemia leads to bone-marrow dysfunction and anaemia. Therefore, the anaemia is a result of the marrow not producing the erythrocytes properly. In addition, the sickle cells cannot differentiate and mature to become functional erythrocytes.
A few new discoveries include the use of immunotherapy with granulocyte colony-stimulating factor in a few clinical trials, and the use of iron depleting agents such as ferroportin inhibitors as a new treatment for sickle cell anemia. For a more detailed analysis of these discoveries, consider using [cited paper]. While the development of new treatments for anemia and other blood diseases is critical, further advances will probably require many more years before they become available to patients.
Hemoglobin S and/or Hb F levels in families in the USA (n = 1798 families) are less informative than in African-American families and other populations.
There are many known benefits of isoquercetin, however there is no information about it in the US clinical trial database. In order to validate it as a beneficial therapeutic, a clinical trial for isoquercetin is necessary.
Data from a recent study shows that isoquercetin improves quality of life for individuals with sickle cell anemia and anemia. Because isoquercetin is inexpensive, readily available to patients, and is safe for topical use, it could be a promising alternative to iron therapy.
Sickle cell anemia (a form of anemia) is usually diagnosed at the early stage after the first symptom, and can be cured by blood transfusion or chelation agents.
It quercetin might be a valuable adjunct to alleviate anemia in patients undergoing chemotherapy. However, it is also effective in its own right without any other effect than what is observed with quercetin. The clinical significance of this effect will be determined when larger and longer clinical studies are conducted in the future.